DeCure's autonomous Dermatology AI scientist is researching a drug-repurposing hypothesis for dyskeratosis congenita, X-linked — screening already-approved drugs against its 3-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleDyskeratosis congenita, X-linked maps to a 3-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for dyskeratosis congenita, x-linked is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
regulator of telomere elongation helicase 1 (RTEL1) — RTEL1 is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet apo structuredrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 8P8H · 2.3 Å · ligand none (apo structure). Experimental structure, not a prediction.
What the evidence adds up to
Two male patients in a Japanese family with X-linked dyskeratosis congenita carried the same novel missense mutation L398P in the DKC1 gene, yet one had significantly milder haematological symptoms than the other, suggesting that other factors modify disease severity. A sporadic case of dyskeratosis congenita presented with the classic cutaneous triad of reticulate skin pigmentation, nail dystrophy and oral leukoplakia, and the authors note the disease can involve haematological, gastrointestinal, genitourinary, neurological, ophthalmic, pulmonary and skeletal systems. A 35-year-old Japanese man with X-linked dyskeratosis congenita had a late presentation and a substitution of methionine to threonine at position 350 in the dyskerin protein; typical cases show abnormal skin pigmentation and nail changes by age 10, with bone marrow failure and death before age 20 and 40 respectively.
No drug treatment is tested or mentioned in any of these abstracts. No clinical trial data, no survival rates, no response rates are reported. The abstracts describe only genetic findings and clinical presentations.
What is still missing: any clinical trial testing a drug for dyskeratosis congenita, any preclinical or animal study of a repurposed compound, any systematic patient stratification by mutation type or modifier genes, and any funding for such work.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Pediatric Hematology and Oncology · 2002 · 20 citations
A NOVEL MISSENSE MUTATION IN THE DKC1 GENE IN A JAPANESE FAMILY WITH X-LINKED DYSKERATOSIS CONGENITA
AbstractThe authors report 2 male patients with dyskeratosis congenita (DC) in a Japanese kindred. Sequencing of the complementary DNA of the dyskerin gene (DKC1) revealed a T-to-C transition at nucleotide 1285 in exon 12 that resulted in a novel missense mutation L398P. Despite harboring the same mutation in the DKC1 gene, one patient had significantly milder hematological symptoms than the other, indicating that there may be other factors that determine the severity of DC.
BMJ Case Reports · 2018 · 9 citations · open access
Dyskeratosis congenita: presentation of cutaneous triad in a sporadic case
AbstractDyskeratosis congenita (DKC) also known as Zinsser-Cole-Engman syndrome is a progressive genetic disease with a classical presentation characterised by a triad of reticulate pigmentation of skin, nail dystrophy and leukoplakia. It may be a multisystem disease with the involvement of haematological, gastrointestinal, genitourinary, neurological, ophthalmic, pulmonary and skeletal system. We report a sporadic case of DKC presenting with poikiloderma, nail dystrophy and oral leukoplakia.
European Journal of Dermatology · 2015 · 3 citations
Late presentation of X-linked dyskeratosis congenita with a missense mutation in codon 350 of the dyskerin protein
AbstractX-linked dyskeratosis congenita (DC) is an inherited disease caused by mutations in the DKC1 gene[1]. In typical cases, abnormal skin pigmentation and nail changes usually appear first, often by 10 years of age, with bone marrow failure and death developing before 20 and 40 years of age, respectively [2]. We report a patient with X-linked DC with a late presentation, where a substitution of methionine to threonine at position 350 in the dyskerin protein was found.A 35-year-old Japanese male presented [...]
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
